Skip to main content

Table 1 Baseline characteristics of study patients (n = 90)

From: Patient expectations, experiences and satisfaction with nintedanib and pirfenidone in idiopathic pulmonary fibrosis: a quantitative study

  Nintedanib (n = 39) Pirfenidone (n = 51) p-value
Age, years 70 (7) 72 (7) 0.22
Male sex – no. (%) 35 (90) 47 (92) 0.72
FVC % predicted 86 (16) 76 (16) 0.01
FVC (L) 3.4 (0.9) 2.9 (0.6) 0.01
DLCO % predicted 48 (14) 49 (14) 0.69
K-BILD total score 56.5 (9) 56.7 (10) 0.89
EQ 5D-Index value 0.78 (0.15) 0.77 (0.19) 0.78
EQ5D-VAS scale 65 (24) 63 (23) 0.66
VAS – cough* 4.8 (2.6) 4.6 (2.5) 0.66
VAS – dyspnea* 5.1 (2.3) 5.6 (2.4) 0.43
VAS – general complaints** 5.6 (2.4) 5.5 (2.4) 0.75
HADS – depression score 3.0 (3.1) 3.9 (3.5) 0.21
HADS – anxiety score 4.7 (2.3) 4.6 (2.3) 0.94
  1. Data are presented as mean (SD). FVC forced vital capacity, DLCO diffusion capacity of the lung for carbon monoxide, K-BILD King’s Brief Interstitial Lung Disease questionnaire, VAS visual analogue scale, HADS Hospital Anxiety and Depression Scale. * a higher score represent worse symptoms, ** a higher score represents fewer symptoms